Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer Beats 1Q Profit Forecasts, but Sales Dip Misses Views

By LINDA A. JOHNSON , AP Medical Writer | May 3, 2017

Pfizer beat Wall Street expectations for first-quarter profit thanks to reduced spending on operations and legal costs, along with strong sales of key new drugs and longtime blockbuster pain treatment Lyrica.

But the top U.S. drugmaker had a disappointing revenue dip of 1 percent as competition hurt overseas sales of the immune disorder drug Enbrel. Sales of Prevnar 13, the top-selling vaccine in history, fell 7 percent to $1.4 billion.

Pfizer continued its aggressive pursuit of companies that can boost its sales and its pipeline of future drugs, completing three significant deals — two purchases and a sale — since January of 2016. That makes year-over-year comparisons rather muddy.

But the New York company on Tuesday posted a quarterly profit of $3.12 billion, or 51 cents per share, up from $3.04 billion, or 49 cents per share, a year earlier. Earnings, adjusted for non-recurring costs, came to 69 cents per share, two cents more than analysts surveyed by Zacks Investment Research expected.

The Viagra maker posted revenue of $12.78 billion in the period, falling short of forecasts for $13.04 billion.

Revenue from Pfizer’s patent-protected newer drugs rose 5 percent to $7.42 billion. Prevnar 13, despite the sales slump, remained Pfizer’s biggest seller, with $1.4 billion in sales. The company also brought in $1.13 billion from fibromyalgia and pain treatment Lyrica, which was up 7 percent, and $679 million from new breast cancer drug Ibrance, up 59 percent.

Sales for the Pfizer division that sells older drugs with expired patents fell 10 percent, to $5.36 billion.

The company benefited from a big jump in alliance revenue from its partners, up 82 percent to $656 million. That includes sales of heavily advertised clot-preventing heart drug Eliquis, which Pfizer sells together with Bristol-Myers Squibb Co.

Pfizer Inc. reaffirmed its January forecast for full-year earnings between $2.50 and $2.60 per share, with revenue between $52 billion and $54 billion.

Elements of this story were generated by Automated Insights using data from Zacks Investment Research.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE